IE
EIKN

Israel Englander’s Eikon Therapeutics EIKN Stock Holding History

Israel Englander’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.74M Sell
133,020
-42,607
-24% -$435K ﹤0.01% 3926
2026
Q1 		$1.86M Buy
+175,627
New +$2.35M ﹤0.01% 3935

Other funds holding EIKN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Israel Englander's EIKN Position: Q2 2026 in Review

Israel Englander reduced its Eikon Therapeutics (EIKN) stake by 24% in Q2 2026, selling an estimated $435K and leaving 133,020 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #3926.

Israel Englander first reported a position in EIKN in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.86M in Q1 2026. 76 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

  • Israel Englander held 133,020 shares of Eikon Therapeutics worth $1.74M as of Q2 2026.
  • Israel Englander sold 42,607 Eikon Therapeutics shares in Q2 2026, an estimated $435K.
  • Eikon Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3926 holding.
  • Israel Englander first reported a position in Eikon Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Israel Englander's Eikon Therapeutics position peaked at $1.86M in Q1 2026.
  • 76 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.